These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH; Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070 [TBL] [Abstract][Full Text] [Related]
7. Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children. Fujinaga S; Kaneko K; Ohtomo Y; Murakami H; Takada M; Akashi S; Hira M; Yamashiro Y Pediatr Nephrol; 2005 Oct; 20(10):1500-3. PubMed ID: 16021476 [TBL] [Abstract][Full Text] [Related]
8. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Lin CY; Hsu HC; Chiang H Nephron; 1989; 53(4):303-10. PubMed ID: 2481240 [TBL] [Abstract][Full Text] [Related]
9. Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Yumura W; Suganuma S; Uchida K; Moriyama T; Otsubo S; Takei T; Naito M; Koike M; Nitta K; Nihei H Clin Nephrol; 2005 Jul; 64(1):28-34. PubMed ID: 16047642 [TBL] [Abstract][Full Text] [Related]
10. Methylprednisolone pulse therapy in Japanese children with severe lupus nephritis. Tanaka H; Tateyama T; Waga S Pediatr Nephrol; 2001 Oct; 16(10):817-9. PubMed ID: 11605789 [TBL] [Abstract][Full Text] [Related]
11. Predictive factors of clinical outcome in patients with diffuse proliferative lupus nephritis treated early by intravenous methylprednisolone pulse therapy. Kanno A; Hotta O; Yusa N; Taguma Y Ren Fail; 2007; 29(1):41-7. PubMed ID: 17365909 [TBL] [Abstract][Full Text] [Related]
12. Management of lupus nephritis at the Kenyatta National Hospital. Otieno LS; McLigeyo SO; Kayima JK; Sitati S East Afr Med J; 1990 Jun; 67(6):387-95. PubMed ID: 2279466 [TBL] [Abstract][Full Text] [Related]
14. Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis. Tanaka H; Tsugawa K; Nakahata T; Kudo M; Suzuki K; Ito E Clin Nephrol; 2005 Jun; 63(6):417-22. PubMed ID: 15960142 [TBL] [Abstract][Full Text] [Related]
15. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Tse KC; Lam MF; Tang SC; Tang CS; Chan TM Lupus; 2007; 16(1):46-51. PubMed ID: 17283585 [TBL] [Abstract][Full Text] [Related]
17. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. Barron KS; Person DA; Brewer EJ; Beale MG; Robson AM J Pediatr; 1982 Jul; 101(1):137-41. PubMed ID: 7045314 [TBL] [Abstract][Full Text] [Related]
18. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Hill GS; Delahousse M; Nochy D; Tomkiewicz E; Rémy P; Mignon F; Méry JP Kidney Int; 2000 Sep; 58(3):1160-73. PubMed ID: 10972679 [TBL] [Abstract][Full Text] [Related]
19. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Anders HJ; Rovin B Kidney Int; 2016 Sep; 90(3):493-501. PubMed ID: 27378475 [TBL] [Abstract][Full Text] [Related]
20. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Grootscholten C; Ligtenberg G; Hagen EC; van den Wall Bake AW; de Glas-Vos JW; Bijl M; Assmann KJ; Bruijn JA; Weening JJ; van Houwelingen HC; Derksen RH; Berden JH; Kidney Int; 2006 Aug; 70(4):732-42. PubMed ID: 16820790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]